FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387208701> ?p ?o ?g. }

• W4387208701 abstract "Age-related macular degeneration (AMD) is a leading cause of severe vision loss worldwide, with a global prevalence that is predicted to substantially increase. Identifying early biomarkers indicative of progression risk will improve our ability to assess which patients are at greatest risk of progressing from intermediate AMD (iAMD) to vision-threatening late-stage AMD. This is key to ensuring individualized management and timely intervention before substantial structural damage. Some structural biomarkers suggestive of AMD progression risk are well established, such as changes seen on color fundus photography and more recently optical coherence tomography (drusen volume, pigmentary abnormalities). Emerging biomarkers identified through multimodal imaging, including reticular pseudodrusen, hyperreflective foci, and drusen sub-phenotypes, are being intensively explored as risk factors for progression towards late-stage disease. Other structural biomarkers merit further research, such as ellipsoid zone reflectivity and choriocapillaris flow features. The measures of visual function that best detect change in iAMD and correlate with risk of progression remain under intense investigation, with tests such as dark adaptometry and cone-specific contrast tests being explored. Evidence on blood and plasma markers is preliminary, but there are indications that changes in levels of C-reactive protein and high-density lipoprotein cholesterol may be used to stratify patients and predict risk. With further research, some of these biomarkers may be used to monitor progression. Emerging artificial intelligence methods may help evaluate and validate these biomarkers; however, until we have large and well-curated longitudinal data sets, using artificial intelligence effectively to inform clinical trial design and detect outcomes will remain challenging. This is an exciting area of intense research, and further work is needed to establish the most promising biomarkers for disease progression and their use in clinical care and future trials. Ultimately, a multimodal approach may yield the most accurate means of monitoring and predicting future progression towards vision-threatening, late-stage AMD. Age-related macular degeneration, or AMD, is an eye disease that causes vision loss. Worldwide, the number of people with AMD is increasing. It is difficult for doctors to know who, among those with AMD, will get worse and lose some of their sight, and who will not. Researchers are trying to find early signs that predict whether AMD will get worse and ways to track AMD progression over time. These signs are known as “biomarkers.” They can be structural (seen in the structures inside the eye), functional (a change in how well someone sees), genetic, or proteins found in the blood. Being able to identify people with AMD that are most at risk of losing their vision will help to make sure they get more frequent review so that interventions can be started quickly before vision is lost permanently. Some structural and functional biomarkers are already well known, while others may be useful and are being intensively researched. Changes in the blood markers need much more research to be useful. Researchers are also looking at how to combine data from different biomarkers. This may be a better way to follow worsening of AMD over time compared to using a single biomarker. In the future, we may also be able to use artificial intelligence to help combine all biomarker data. This is an exciting area of research that will be important to help improve the vision outcomes for people with AMD." @default.
• W4387208701 created "2023-09-30" @default.
• W4387208701 creator A5030132149 @default.
• W4387208701 creator A5051997081 @default.
• W4387208701 creator A5073703088 @default.
• W4387208701 date "2023-09-29" @default.
• W4387208701 modified "2023-10-14" @default.
• W4387208701 title "Biomarkers for the Progression of Intermediate Age-Related Macular Degeneration" @default.
• W4387208701 cites W159419684 @default.
• W4387208701 cites W1658498556 @default.
• W4387208701 cites W180947891 @default.
• W4387208701 cites W183193446 @default.
• W4387208701 cites W1961778296 @default.
• W4387208701 cites W1964287112 @default.
• W4387208701 cites W1965902690 @default.
• W4387208701 cites W1970714860 @default.
• W4387208701 cites W1971449134 @default.
• W4387208701 cites W1972642682 @default.
• W4387208701 cites W1975339399 @default.
• W4387208701 cites W1976041506 @default.
• W4387208701 cites W1981111037 @default.
• W4387208701 cites W1987772140 @default.
• W4387208701 cites W1995478859 @default.
• W4387208701 cites W1995575842 @default.
• W4387208701 cites W2000076612 @default.
• W4387208701 cites W2001447737 @default.
• W4387208701 cites W2005450539 @default.
• W4387208701 cites W2011845506 @default.
• W4387208701 cites W2019947342 @default.
• W4387208701 cites W2020344616 @default.
• W4387208701 cites W2021311336 @default.
• W4387208701 cites W2024016853 @default.
• W4387208701 cites W2040208249 @default.
• W4387208701 cites W2052543124 @default.
• W4387208701 cites W2056000744 @default.
• W4387208701 cites W2057550914 @default.
• W4387208701 cites W2060971545 @default.
• W4387208701 cites W2092638574 @default.
• W4387208701 cites W2096060458 @default.
• W4387208701 cites W2096543412 @default.
• W4387208701 cites W2111379072 @default.
• W4387208701 cites W2113404906 @default.
• W4387208701 cites W2125880559 @default.
• W4387208701 cites W2138437064 @default.
• W4387208701 cites W2138903426 @default.
• W4387208701 cites W2146800041 @default.
• W4387208701 cites W2147322584 @default.
• W4387208701 cites W2156595418 @default.
• W4387208701 cites W2160226180 @default.
• W4387208701 cites W2165569080 @default.
• W4387208701 cites W2172569937 @default.
• W4387208701 cites W2179516852 @default.
• W4387208701 cites W2191055194 @default.
• W4387208701 cites W2233221674 @default.
• W4387208701 cites W2289254711 @default.
• W4387208701 cites W2291910723 @default.
• W4387208701 cites W2302226642 @default.
• W4387208701 cites W2313055258 @default.
• W4387208701 cites W2323021211 @default.
• W4387208701 cites W2336818263 @default.
• W4387208701 cites W2346937987 @default.
• W4387208701 cites W2397880192 @default.
• W4387208701 cites W2469055289 @default.
• W4387208701 cites W2517886648 @default.
• W4387208701 cites W2518556710 @default.
• W4387208701 cites W2532486111 @default.
• W4387208701 cites W2551016387 @default.
• W4387208701 cites W2558511977 @default.
• W4387208701 cites W2559171561 @default.
• W4387208701 cites W2565136318 @default.
• W4387208701 cites W2598520882 @default.
• W4387208701 cites W2604482039 @default.
• W4387208701 cites W2607490066 @default.
• W4387208701 cites W2734931180 @default.
• W4387208701 cites W2735396028 @default.
• W4387208701 cites W2738996050 @default.
• W4387208701 cites W2749678738 @default.
• W4387208701 cites W2754237037 @default.
• W4387208701 cites W2758418434 @default.
• W4387208701 cites W2762494246 @default.
• W4387208701 cites W2766820003 @default.
• W4387208701 cites W2802796937 @default.
• W4387208701 cites W2804685255 @default.
• W4387208701 cites W2844103009 @default.
• W4387208701 cites W2847659972 @default.
• W4387208701 cites W2864396222 @default.
• W4387208701 cites W2886778205 @default.
• W4387208701 cites W2886969976 @default.
• W4387208701 cites W2888928552 @default.
• W4387208701 cites W2891443166 @default.
• W4387208701 cites W2896734556 @default.
• W4387208701 cites W2898456150 @default.
• W4387208701 cites W2905721453 @default.
• W4387208701 cites W2907906577 @default.
• W4387208701 cites W2910251362 @default.
• W4387208701 cites W2924374658 @default.
• W4387208701 cites W2938857728 @default.
• W4387208701 cites W2953454923 @default.
• W4387208701 cites W2953774200 @default.
• W4387208701 cites W2962788992 @default.

• next